Increased Mortality and Cardiovascular Morbidity Associated With Use of Nonsteroidal Anti-inflammatory Drugs in Chronic Heart Failure

Gunnar H. Gislason, MD, PhD; Jeppe N. Rasmussen, MD, PhD; Steen Z. Abildstrom, MD, PhD; Tina K. Schramm, MD; Morten L. Hansen, MD; Emil L. Fosbol, MB; Rikke Sørensen, MD; Fredrik Folke, MD; Pernille Buch, MD, PhD; Niels Gadgoogle, MD, DMSc; Søren Rasmussen, MSc, PhD; Henrik E. Poulsen, MD, DMSc; Lars Køber, MD, DMSc; Mette Madsen, MSc; Christian Torp-Pedersen, MD, DMSc

Background: Accumulating evidence indicates increased cardiovascular risk associated with nonsteroidal anti-inflammatory drug (NSAID) use, in particular in patients with established cardiovascular disease. We studied the risk of death and hospitalization because of acute myocardial infarction and heart failure (HF) associated with use of NSAIDs in an unselected cohort of patients with HF.

Methods: We identified 107,092 patients surviving their first hospitalization because of HF between January 1, 1995, and December 31, 2004, and their subsequent use of NSAIDs from individual-level linkage of nationwide registries of hospitalization and drug dispensing by pharmacies in Denmark. Data analysis was performed using Cox proportional hazard models adjusted for age, sex, calendar year, comorbidity, medical treatment, and severity of disease, and propensity-based risk-stratified models and case-crossover models.

Results: A total of 36,354 patients (33.9%) claimed at least 1 prescription of an NSAID after discharge; 60,974 (56.9%) died, and 39,984 (37.5%) were hospitalized with myocardial infarction or HF, respectively. The hazard ratio (95% confidence interval) for death was 1.70 (1.58-1.82), 1.75 (1.63-1.88), 1.31 (1.25-1.37), 2.08 (1.95-2.21), 1.22 (1.07-1.39), and 1.28 (1.21-1.35) for rofecoxib, celecoxib, ibuprofen, diclofenac, naproxen, and other NSAIDs, respectively. Furthermore, there was a dose-dependent increase in risk of death and increased risk of hospitalization because of myocardial infarction and HF. Propensity-based risk-stratified analysis and case-crossover models yielded similar results.

Conclusions: NSAIDs are frequently used in patients with HF and are associated with increased risk of death and cardiovascular morbidity. Inasmuch as even commonly used NSAIDs exerted increased risk, the balance between risk and benefit requires careful consideration when any NSAID is given to patients with HF.

Arch Intern Med. 2009;169(2):141-149

Since publication of the Vioxx Gastrointestinal Outcomes Research (VIGOR) Study in 2000, debate has been ongoing about increased cardiovascular risk of nonsteroidal anti-inflammatory drugs (NSAIDs), in particular, the selective cyclooxygenase-2 (COX-2) inhibitors. Clinical guidelines discourage use of NSAIDs in patients with chronic heart failure (HF) owing to increased risk of fluid retention and worsening of HF. Recent recommendations from the American Heart Association are to avoid administration of selective COX-2 inhibitors in patients with established or increased risk of cardiovascular disease and to consider alternative pain medications before using NSAIDs in this population. Patients receiving NSAIDs are often elderly, frequently have other concurrent medical illnesses, and often have multiple cardiovascular risk factors or established cardiovascular disease. Furthermore, many NSAIDs are sold over the counter (OTC) in pharmacies and convenience stores without expert advice about their use and potential drug interactions or adverse effects, which might give the misconception that NSAIDs are harmless.

The widespread use of NSAIDs and the perception of low risk associated with such OTC drugs prompted us to study an unselected cohort of 107,092 patients surviving a first hospitalization because of HF, with particular focus on risk of death and hospitalization as a result of the use of NSAIDs.

The Danish Data Protection Agency approved this study (No. 2003-54-1269). No ethical approval is required for retrospective registry studies in Denmark.
Patients aged 30 years or older who between January 1, 1995, and December 31, 2004, survived their first hospitalization because of HF (International Classification of Diseases, Tenth Revision, codes I11.0, I11.1, I11.2, and I11.3) were identified in the Danish National Patient Registry, which includes records of all hospitalizations in Denmark since 1978. The selection of patients and their characteristics have been described in detail previously. Each patient’s vital status as of December 31, 2004, was obtained from the Central Population Registry.

### Table 1. Baseline Characteristics of the Study Sample According to Exposure Group

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Total Population, No. (%)</th>
<th>No NSAID</th>
<th>Rofecoxib</th>
<th>Celecoxib</th>
<th>Ibuprofen</th>
<th>Diclofenac</th>
<th>Naproxen</th>
<th>Other NSAIDs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total No. of patients</td>
<td>107 092</td>
<td>70 738</td>
<td>6161</td>
<td>5734</td>
<td>16 975</td>
<td>9377</td>
<td>2176</td>
<td>11 488</td>
</tr>
<tr>
<td>Age, mean (SD), y</td>
<td></td>
<td>74.8 (11.6)</td>
<td>75.5 (11.5)</td>
<td>75.2 (10.8)</td>
<td>74.6 (10.8)</td>
<td>72.1 (12.1)</td>
<td>71.7 (11.9)</td>
<td>72.2 (12.0)</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td>Male</td>
<td>55 368 (51.7)</td>
<td>36 852 (26.1)</td>
<td>26 032 (426.2)</td>
<td>25794 (245.2)</td>
<td>9237 (54.4)</td>
<td>5710 (55.1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Female</td>
<td>51 724 (48.3)</td>
<td>33 884 (47.9)</td>
<td>35135 (57.4)</td>
<td>32894 (57.4)</td>
<td>7738 (45.6)</td>
<td>2407 (42.4)</td>
</tr>
</tbody>
</table>

### Year of first hospitalization

- **1995-1996**: 19 789 (18.5), 11 924 (16.9), 780 (12.8), 610 (10.8), 4345 (25.6), 2266 (23.7), 723 (33.2), 3148 (27.4)
- **1997-1998**: 19 996 (18.6), 12 300 (17.4), 1131 (18.5), 920 (16.0), 3817 (22.5), 2524 (24.1), 497 (22.8), 2792 (24.3)
- **1999-2000**: 22 588 (21.1), 13 882 (19.6), 1937 (31.7), 1702 (29.7), 3685 (22.8), 2269 (24.2), 472 (21.7), 2601 (22.6)
- **2001-2002**: 23 257 (21.7), 15 284 (21.6), 1761 (28.8), 1770 (30.9), 3211 (19.9), 1791 (19.1), 328 (15.1), 1901 (16.5)
- **2003-2004**: 21 462 (20.1), 17 348 (24.5), 723 (12.6), 1737 (10.2), 837 (8.9), 156 (7.2), 1046 (9.1)

### Concomitant therapy

- **Antidiabetes agents**: 13 387 (12.5), 8843 (12.5), 715 (11.7), 752 (13.1), 2187 (12.9), 1134 (12.1), 246 (11.3), 1411 (12.3)
- **Statins**: 13 084 (12.2), 8611 (12.2), 714 (11.7), 748 (13.0), 2185 (12.9), 1211 (12.9), 240 (11.0), 1218 (10.6)
- **Spironolactone**: 20 166 (18.8), 13 892 (19.6), 1079 (17.6), 1108 (19.3), 2778 (16.4), 1549 (16.5), 355 (15.4), 1920 (15.8)
- **β-Blockers**: 29 084 (27.2), 19 041 (26.9), 1754 (28.7), 1762 (30.7), 5611 (27.2), 2679 (28.6), 562 (25.8), 2946 (25.6)
- **ACE inhibitors or ARBs**: 46 191 (41.1), 29 645 (41.9), 2777 (45.4), 2601 (45.6), 7685 (45.1), 4264 (45.0), 940 (43.2), 5188 (45.2)
- **Diuretics**: 24 817 (23.2), 15 927 (22.5), 1500 (24.5), 1486 (24.5), 4099 (24.2), 2107 (23.5), 585 (26.9), 2844 (24.8)
- **Hemiplegia or paraplegia**: 128 (0.1), 93 (0.1), 3 (0.05), 3 (0.05), 17 (0.1), 11 (0.1), 2 (0.1), 11 (0.1)
- **Dementia**: 82 (0.1), 60 (0.1), 4 (0.07), 4 (0.07), 8 (0.05), 5 (0.05), 0, 6 (0.05)
- **AIDS**: 1827 (17.5), 1026 (1.5), 212 (3.5), 191 (3.3), 277 (1.6), 146 (1.6), 35 (1.6), 207 (1.8)

### Charlson Comorbidity Index score, mean (SD)

- **1**: 26 543 (24.8), 18 814 (26.6), 1281 (20.9), 1265 (22.1), 3669 (21.6), 2088 (22.3), 443 (20.4), 2222 (20.2)
- **2**: 42 543 (24.8), 18 814 (26.6), 1281 (20.9), 1265 (22.1), 3669 (21.6), 2088 (22.3), 443 (20.4), 2222 (20.2)
- **3**: 26 543 (24.8), 18 814 (26.6), 1281 (20.9), 1265 (22.1), 3669 (21.6), 2088 (22.3), 443 (20.4), 2222 (20.2)
- **4**: 13 185 (12.3), 9769 (13.8), 531 (8.7), 448 (7.8), 1549 (9.1), 818 (8.7), 208 (9.8), 1130 (9.8)

### Methods

The Danish Registry of Medicinal Product Statistics, a national prescription registry, comprises all prescriptions dispensed from Danish pharmacies since 1995, which are directly and automatically linked to reimbursement of medication expenses, ensuring complete registration. Coding is according to the Anatomical Therapeutical Chemical (ATC) Classification System. The national prescription registry does not include information about prescribed daily dosage of medications. Therefore, by calculating mean dosages from up to 3 consecutive prescriptions, the daily dosage was estimated for each new prescription claim. In cases in which only 1 prescription was available, the mean dosage was the minimum predefined daily dosage.
age for each drug. This method allowed for dosages to be changed at dispensing of a new prescription. The method has been described in detail previously.\textsuperscript{15,16}

From the national prescription registry, all claimed prescrip-
tions of NSAIDs (ATC code M01A) by the study cohort were identified. The most frequently used selective COX-2 inhibitors, rofe-
ocoxib (M01AH02) and celecoxib (M01AH01), and nonsel-
ective NSAIDs, ibuprofen (M01AE01) and diclofenac (M01AB05), were analyzed separately because they represented most of the se-
lective COX-2 inhibitors and nonsel- ective NSAIDs used. In addi-
tion, the nonsel ective NSAID naproxen (M01AE02) was anal-
alyzed separately to gain further knowledge about the cardio-
vascular risk associated with this NSAID. Rofecoxib, cele-
coxib, ibuprofen, diclofenac, and naproxen were classified as low or high dosages in the analyses. The upper limit of low dosage was defined as the lower recommended daily dose for the individual NSAIDs, that is, 25 mg for rofecoxib, 200 mg for cele-
coxib, 1200 mg for ibuprofen, 100 mg for diclofenac, and 500 mg for naproxen. Other NSAIDs, not including glucosamine (M01AX05), were categorized as 1 group in the analyses, with-
out dosage specification. We defined concomitant treatment status with the following cardiovascular drugs: angiotensin-
converting enzyme inhibitors and angiotensin-2 receptor blockers (ATC C09 ACEi/ARBs), \( \beta \)-blockers (ATC C07), and spirono-
lactone (ATC C03D) as prescriptions claimed within 90 days af-
ter discharge, and statins (ATC C10AA) claimed within 180 days af-
ter discharge.

To quantify the severity of HF or severity of accompanying renal failure, patients were classified into 4 groups according to the mean daily dose of loop diuretics (ATC C03C) used within the first 90 days after discharge (furosemide equivalent dosage: furosemide, 40 mg = bumetanide, 1 mg): group 1, 0 to 39 mg; group 2, 40 to 80 mg; group 3, 81 to 160 mg; and group 4, more than 160 mg.\textsuperscript{15,17} Pharmacologically treated diabetes was identified from prescriptions of glucose-lowering mediation (ATC A10) from 90 days before admission to 90 days after discharge.

**COMORBIDITY**

The Charlson Comorbidity Index, modified for the Interna-
tional Classification of Diseases, Tenth Revision, was used to de-
fine comorbidity (Table 1).\textsuperscript{18,19} The Charlson Comorbidity in-
dex was estimated at discharge and further enhanced by including diagnoses up to 1 year before this index hospitalization.

**STATISTICAL ANALYSIS**

Time to death, and hospitalization because of myocardial infarction (MI) or HF were estimated using Cox proportional haz-
ards regression models, including exposure to drug of interest as time-dependent covariates in the models (ie, patients were only consid-
ered at risk when they were taking the drug). The models al-
lowed patients to switch from 1 specific NSAID to another specific NSAID, thereby changing exposure status. The models also permitted concomitant use of different NSAIDs; however, combinations were not analyzed specifically. The Cox propor-
tional hazards regression models were adjusted for age, sex, calendar year, duration of exposure, concomitant medical treat-
ment, and comorbidity. The proportional hazard assumption is invalid in time-dependent proportional hazard models; how-
ever, the linearity of continuous variables and lack of interac-
tion were tested and found valid unless otherwise indicated.

As a sensitivity analysis, we performed risk-stratified analysis by ranking the patients into tertiles according to an estimated prop-
pensity score for death within 1 year after discharge. The prop-
pensity score was estimated using logistic regression analysis condi-
tional on baseline covariates. Furthermore, to ensure the robustness of our findings, the analyses were repeated using case-
crossover models.\textsuperscript{20} The case-crossover analysis includes only pa-
tients experiencing an event; however, rather than using matched control subjects, the case serves as its own control, thereby re-
ducing the effect of unmeasured confounders. The case period was defined as 0 to 30 days before the event (death or hospital-
ization because of MI or HF), and control periods as 60 to 90 days and 90 to 120 days before the event.

Mortality was calculated as deaths per 1000 person-years exposed. The number needed to harm was estimated for each drug from the unadjusted mortality as number needed to harm per 1000 person-years exposed. All statistical calculations were performed using commercially available software (SAS version 9.1; SAS Institute, Inc, Cary, North Carolina).

**RESULTS**

A total of 107 092 patients with HF were identified and included in the study. Of these, 36 354 patients (33.9%) received at least 1 prescription of either a selective COX-2 inhibitor or a nonsel ective NSAID. Baseline characteristics are given in Table 1. Table 2 lists the duration of...
treatment with individual drugs and median doses. The median duration of treatment of individual NSAIDs varied between 42 and 97 days (Table 2).

**MORTALITY**

A total of 60,974 (56.9%) patients died during the study. Mortality, absolute risk increase, and number needed to harm related to each exposure group are listed in Table 2. There was an increased risk of death associated with treatment with most NSAIDs. The increase in risk was highest for rofecoxib, celecoxib, and diclofenac. This was confirmed in multivariate Cox proportional hazards regression analysis (Table 3 and Figure 1), with a clear dose-dependent increase in risk. Low doses of ibuprofen and naproxen were not associated with increased mortality risk, although high doses of both of these drugs were associated with an increased risk of death.

**HOSPITALIZATION BECAUSE OF MI**

Hospitalization because of MI occurred in 8970 patients (8.4%). An increased risk of MI was associated with treatment with both selective COX-2 inhibitors and nonselective NSAIDs (Table 3 and Figure 2), and hazard ratios were similar for all types of NSAIDs. A dose-
dependent increase in risk of MI was evident with rofecoxib and diclofenac.

HOSPITALIZATION BECAUSE OF HF

A total of 39,984 patients (37.5%) were hospitalized because of HF. All of the drugs were associated with an increased risk of hospitalization because of HF (Table 3 and Figure 3). Rofecoxib was associated with the highest risk and demonstrated a dose-dependent increase in risk.

CASE-CROSSOVER ANALYSIS

Repeating the analysis using case-crossover models generated similar results (Table 4) as with Cox proportional hazards regression analysis.

SENSITIVITY ANALYSES

Figure 4 shows the hazard ratios for death within 1 year after discharge across tertiles of risk of death as defined by baseline variables. The C statistic was 0.72, indicating good discriminatory power of the models to differentiate strata of risk. The increased risk associated with NSAID therapy was present at all strata.

No important interactions were noted between the different exposure groups and subgroups of patients. In particular, we analyzed subgroups of patients receiving prophylactic evidence-based pharmacotherapy (angiotensin-converting enzyme inhibitors, β-blockers, spironolactone, and statins) and found no indication for effect modification in risk associated with use of these drugs. Also, we found no interaction in risk between patients who did or did not have previous acute MI.

We found increased mortality and increased risk of hospitalization because of MI or HF related to NSAID use in an unselected cohort of patients discharged alive after their first hospitalization because of HF. The risk was
increased for all of the selective COX-2 inhibitors and diclofenac, and for ibuprofen and naproxen in high doses. A causative relationship was indicated by a dose-dependent increase in risk. The extensive absolute increase in risk of 11.1% for rofecoxib, 7% for celecoxib, and 9% for diclofenac, and the low number needed to harm are worrisome, in particular because 34% of patients with HF received a prescription for an NSAID. Apparently awareness is low among physicians concerning international clinical recommendations that discourage use of NSAIDs in patients with HF.

Most of the current knowledge of the cardiovascular risk of use of NSAID therapy is based on post hoc analyzes and analysis of subgroups of patients from studies designed to examine noncardiovascular diseases; however, to our knowledge, with the exception of 1 study, no clinical trials have primarily been designed to address the cardiovascular risk with use of NSAIDs. Focus has primarily been on the COX-2 inhibitors, whereas the cardiovascular risk with use of nonselective NSAIDs is estimated primarily from observational studies and meta-analyses. In the future, the discrepancy in results of randomized trials and observational studies may be resolved by the Prospective Randomized Evaluation of Celecoxib Integrated Safety vs Ibuprofen or Naproxen (PRECISION) Trial, which currently is recruiting patients.

The biological effects of NSAIDs have been discussed in detail previously. In brief, NSAIDs inhibit cyclooxygenase, which by 2 separate pathways promotes the synthesis of thromboxanes (COX-1) and prostaglandins (COX-2) from arachidonic acid. It has been proposed that excessive cardiovascular risk with use of NSAIDs is due primarily to an imbalance in inhibition of these pathways. The various NSAIDs have different abilities for inhibition of COX-1 and COX-2, and the more COX-2-selective NSAIDs seem to have a more cardiotoxic effect. Furthermore, there seems to be marked interindividual variability in the response to selective COX-2 inhibition, which might interfere with the susceptibility to cardiovascular risk, which also is more pronounced in patients with established cardiovascular disease. Focus has primarily been on the increased thromboembolic risk, although other properties of NSAIDs could influence the risk in patients with HF. NSAIDs influence renal function and the regulation of fluid balance, causing fluid retention and worsening of HF, in addition to promoting increased risk of hypertension and destabilization of blood pressure. Animal models have demonstrated that COX-2 inhibition can induce structural changes in the myocardium and enhance left ventricular remodeling, impair systolic function, and increase mortality after MI. Regulation of fluid balance and blood pressure is of particular importance in chronic HF; thus, NSAIDs might tip the balance and worsen HF, and in the worst-case scenario, lead to a fatal outcome. A causative relationship between NSAID use and cardiovascular risk in patients with established HF is, therefore, highly plausible.

Agreement is general regarding increased cardiovascular risk with the selective COX-2 inhibitor rofecoxib, whereas the risk with celecoxib has been debated. We have previously found increased risk with celecoxib in a cohort of patients after MI, and Brophy et al demonstrated that celecoxib was harmful only in patients who had an MI. Hudson et al found that celecoxib

### Table 4. Odds Ratios for Death, and Hospitalization Because of HF or AMI

<table>
<thead>
<tr>
<th>Drug</th>
<th>OR (95% CI)</th>
<th>P Value</th>
<th>OR (95% CI)</th>
<th>P Value</th>
<th>OR (95% CI)</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rofecoxib</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any use</td>
<td>1.62 (1.40-1.88)</td>
<td>&lt;.001</td>
<td>2.39 (1.89-3.01)</td>
<td>&lt;.001</td>
<td>1.39 (0.93-2.06)</td>
<td>.11</td>
</tr>
<tr>
<td>≤25 mg/d</td>
<td>1.19 (1.01-1.40)</td>
<td>.03</td>
<td>2.12 (1.67-2.70)</td>
<td>&lt;.001</td>
<td>1.32 (0.88-1.98)</td>
<td>.18</td>
</tr>
<tr>
<td>&gt;25 mg/d</td>
<td>4.99 (3.65-6.84)</td>
<td>&lt;.001</td>
<td>6.17 (3.22-11.82)</td>
<td>&lt;.001</td>
<td>2.73 (0.66-11.32)</td>
<td>.17</td>
</tr>
<tr>
<td>Celecoxib</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any use</td>
<td>1.89 (1.60-2.23)</td>
<td>&lt;.001</td>
<td>1.86 (1.45-2.50)</td>
<td>&lt;.001</td>
<td>1.31 (0.85-2.04)</td>
<td>.23</td>
</tr>
<tr>
<td>≤200 mg/d</td>
<td>1.21 (0.99-1.48)</td>
<td>.06</td>
<td>1.95 (1.49-2.56)</td>
<td>&lt;.001</td>
<td>1.26 (0.77-2.04)</td>
<td>.36</td>
</tr>
<tr>
<td>&gt;200 mg/d</td>
<td>4.11 (3.15-5.38)</td>
<td>&lt;.001</td>
<td>1.48 (0.87-2.54)</td>
<td>.15</td>
<td>1.51 (0.70-3.27)</td>
<td>.29</td>
</tr>
<tr>
<td>Ibuprofen</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any use</td>
<td>1.50 (1.36-1.65)</td>
<td>&lt;.001</td>
<td>1.41 (1.24-1.61)</td>
<td>&lt;.001</td>
<td>1.47 (1.15-1.88)</td>
<td>.002</td>
</tr>
<tr>
<td>≤1200 mg/d</td>
<td>0.89 (0.79-0.99)</td>
<td>.04</td>
<td>1.36 (1.19-1.56)</td>
<td>&lt;.001</td>
<td>1.28 (0.98-1.63)</td>
<td>.07</td>
</tr>
<tr>
<td>&gt;1200 mg/d</td>
<td>6.43 (5.26-7.86)</td>
<td>&lt;.001</td>
<td>1.86 (1.33-2.60)</td>
<td>.003</td>
<td>4.51 (2.28-9.81)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Diclofenac</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any use</td>
<td>2.50 (2.21-2.82)</td>
<td>&lt;.001</td>
<td>1.97 (1.64-2.34)</td>
<td>&lt;.001</td>
<td>1.64 (1.16-2.30)</td>
<td>.005</td>
</tr>
<tr>
<td>≤100 mg/d</td>
<td>1.21 (1.04-1.40)</td>
<td>.01</td>
<td>1.85 (1.52-2.25)</td>
<td>&lt;.001</td>
<td>1.18 (0.81-1.72)</td>
<td>.38</td>
</tr>
<tr>
<td>&gt;100 mg/d</td>
<td>14.69 (10.9-19.7)</td>
<td>&lt;.001</td>
<td>2.90 (1.81-4.64)</td>
<td>&lt;.001</td>
<td>9.10 (3.45-23.98)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Naproxen</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any use</td>
<td>1.20 (0.91-1.58)</td>
<td>.12</td>
<td>1.02 (0.72-1.46)</td>
<td>.90</td>
<td>1.31 (0.64-2.71)</td>
<td>.05</td>
</tr>
<tr>
<td>≤500 mg/d</td>
<td>0.84 (0.60-1.17)</td>
<td>.29</td>
<td>1.03 (0.69-1.53)</td>
<td>.83</td>
<td>1.31 (0.56-3.05)</td>
<td>.54</td>
</tr>
<tr>
<td>&gt;500 mg/d</td>
<td>2.35 (1.51-3.65)</td>
<td>&lt;.001</td>
<td>1.01 (0.53-1.89)</td>
<td>.98</td>
<td>1.33 (0.39-4.50)</td>
<td>.65</td>
</tr>
<tr>
<td>Other NSAID</td>
<td>1.29 (1.15-1.44)</td>
<td>&lt;.001</td>
<td>1.68 (1.44-1.97)</td>
<td>&lt;.001</td>
<td>1.56 (1.16-2.08)</td>
<td>.003</td>
</tr>
</tbody>
</table>

Abbreviations: AMI, acute myocardial infarction; CI, confidence interval; HF, heart failure; NSAID, nonsteroidal anti-inflammatory drug; OR, odds ratio.

*Conditional logistic regression by the case-crossover design. Case period, 0 to 30 days before event; control periods, 60 to 90 days and 90 to 120 days before event.*
increased the risk of hospitalization because of HF similarly to conventional NSAIDs. In 2 meta-analyses, McGettigan and Henry and Kearney et al did not find increased cardiovascular risk with celecoxib therapy. Hence, it seems that celecoxib may be particularly harmful in patients with established cardiovascular disease. Among the conventional nonselective NSAIDs, the cardiovascular risk with naproxen has been much debated, and some reports have suggested that naproxen was cardioprotective because of its similar ability as aspirin to inhibit COX-1. In the present study, naproxen at high dosages was associated with increased mortality and increased risk of hospitalization because of MI and HF. This is in accordance with several other reports, whereas others have not been able to demonstrate increased risk with use of naproxen. However, considering the present results along with the existing evidence, physicians must exert caution in using naproxen in patients with HF, as with other NSAIDs. It is intriguing that the NSAID associated with the highest risk was diclofenac, whose COX-2 selectivity is similar to that of celecoxib. Increased cardiovascular risk with diclofenac has been demonstrated previously, and the present study extends this finding to patients with HF. Particularly worrisome is that diclofenac is a widely used NSAID, and in many countries it is dispensed OTC, which might be misinterpreted to indicate that diclofenac is a harmless drug. Another common NSAID with OTC status is ibuprofen, which we found harmful in high dosages. Ibuprofen can interact with aspirin by competitively inhibiting COX-1 in the thrombocytes. The inhibition by ibuprofen is reversible, whereas aspirin irreversibly inhibits COX-1; hence, ibuprofen can diminish the cardioprotection of aspirin if taken simultaneously. Previous study results have reported an increased risk of hospitalization because of HF associated with NSAID treatment. The present study demonstrates increased mortality and individual differences in risk between the various NSAIDs and dosages. Most patients used NSAIDs for a short time, shortest for the COX-2 inhibitors and diclofenac, which indicates relatively acute cardiotoxic effects of these drugs and is in accord with other reports. We found no indication for effect modification by use of evidence-based pharmacotherapy at baseline for the risk exerted by NSAID treatment. Thus, NSAIDs should be avoided in all patients with HF, regardless of baseline pharmacotherapy.

**STUDY STRENGTHS AND LIMITATIONS**

The main strength of this study is that it includes complete data from an entire nation (Denmark), thus avoiding selection bias by including only subgroups of patients or patients from selected hospitals, medical centers, or health care systems. In Denmark, a government-financed health care system ensures equal access to health care for all inhabitants free. Drug expenses are partially reimbursed, and pharmacies are required to register all dispensed prescriptions in the nationwide prescription registry, ensuring complete registration. Use of OTC NSAID drugs is negligible; ibuprofen is the only NSAID with OTC status in Denmark, and only in low doses (200 mg) and in limited quantity at each dispensing. Hence, patients needing long-term treatment or higher dosages would have an incentive to get a prescription from their physician because only prescribed drugs are covered by the reimbursement policy. Ibuprofen achieved OTC status in October 2001, and in a sensitivity analysis including data only to January 1, 2001, we achieved similar results (data not shown). Thus, OTC use of ibuprofen is unlikely to have major, if any, effects on the present results.

The main limitation of the present study is its observational design. The discharge coding diagnosis of HF has been validated in the Danish National Patient Registry and, in accord with other studies, found to have high specificity but low sensitivity. Thus, the discharge coding diagnosis of HF is suitable to correctly identify patients with HF but not for investigating the prevalence or incidence of HF in a population. Another important limitation is the lack of detailed information about important prognostic factors such as left ventricular ejec-
tion fraction, New York Heart Association classification, smoking, and lipid levels. Although appropriate adjustments were made for comorbidity, the effect of unmeasured confounders can never be fully excluded. In addition, the indication for starting NSAID therapy for each patient is lacking. Thus, the disease or the pain-eliciting condition being treated with an NSAID could indicate a status with increased risk for the patient being treated. However, considering current recommendations that discourage NSAIDs in HF, a channeling bias toward less use of NSAIDs in patients at high risk could be expected because physicians could be more reluctant to use NSAIDs in patients with more severe HF. Comparing baseline characteristics among exposure groups (Table 1), this might be the case because there were fewer patients in severity group 4 using NSAIDs compared with severity groups 1 and 2. The propensity-based risk-stratified analysis yielded similar hazard ratios across all risk groups (Figure 4), with a dose-dependent response (data not shown), and the case-crossover models generated similar results. Thus, confounding by indication alone does not explain the increased risk of NSAID use in this cohort. Furthermore, the difference in risk across different NSAIDs and a dose-dependent increase in risk further supports a causative relationship.

**CONCLUSIONS**

Treatment with NSAIDs, both selective COX-2 inhibitors and nonselective NSAIDs, in patients with chronic HF is associated with increased mortality and cardiovascular morbidity, with a dose-dependent response. Therefore, patients with HF should, if possible, avoid using any NSAIDs at any dosage for most NSAIDs and at high dosages for ibuprofen and naproxen. Treatment in patients with pain conditions relieved by these drugs should be based on a medically competent evaluation of the benefits vs risks of treatment. Patients who depend on using these drugs should preferably use the NSAIDs that are more COX-1 selective, in as low dosages and for as short a period as possible.

Further research is required to establish the cardiovascular risk associated with all NSAIDs in subgroups of patients with cardiovascular disease, particularly if a low dosage with analgesic effect can be used without increased risk. In the meantime, because of the accumulating evidence, general awareness is required among physicians, health care authorities, and the general public about the potential cardiovascular risk of NSAIDs, in particular in patients with established cardiovascular disease or at increased cardiovascular risk.

Accepted for Publication: July 14, 2008.

Author Affiliations: Department of Cardiology, Gentofte University Hospital, Hellerup, Denmark (Drs Gislason, Abildstrom, Schramm, Hansen, Sørensen, Folke, Buch, and Torp-Pedersen, and Mr Fosbol); National Institute of Public Health (Drs J. N. Rasmussen, Abildstrom, Schramm, and S. Rasmussen), Department of Clinical Pharmacology (Dr Poulsen) and Cardiology (Dr Køber), Rigshospitalet—Copenhagen University Hospital, Copenhagen, Denmark; Faculty of Health Sciences (Drs Poulsen, Kober, and Torp-Pedersen) and Institute of Public Health Research (Ms Madsen), University of Copenhagen, Copenhagen; and Department of Medicine, Roskilde County Hospital, Koge (Dr Gadsbøll), Denmark.

Correspondence: Gunnar H. Gislason, MD, PhD, Department of Cardiology, Gentofte University Hospital, Niels Andersens Vej 65, 2900 Hellerup, Denmark (gg@heart.dk).

Author Contributions: Dr Gislason had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Gislason, Abildstrom, Poulsen, Madsen, and Torp-Pedersen. Acquisition of data: Gislason, J. N. Rasmussen, Abildstrom, Madsen, and Torp-Pedersen. Analysis and interpretation of data: Gislason, J. N. Rasmussen, Abildstrom, Schramm, Hansen, Fosbol, Sorensen, Folke, Buch, Gadsbøll, S. Rasmussen, Poulsen, Kober, Madsen, and Torp-Pedersen. Statistical analysis: Gislason, Abildstrom, Fosbol, S. Rasmussen, Kober, Madsen, and Torp-Pedersen. Obtained funding: Gislason, Kober, Madsen, and Torp-Pedersen. Administrative, technical, and material support: Gislason, J. N. Rasmussen, Folke, Poulsen, and Torp-Pedersen. Study supervision: Abildstrom, Poulsen, Madsen, and Torp-Pedersen.

Financial Disclosure: None reported.

**REFERENCES**


